Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Dai
UBS

David Dai

UBS
Wall Street Analyst
★★★☆☆
#1555
on 13Foresight · ranked by our own returns
50%
Success Rate
+16.8%
Average Return
26 of 52 calls profitable · +12.6% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 50% of David Dai's ratings turned a profit when each position was held for 1 year — averaging +16.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

48 Buy 15 Hold 0 Sell
David's Stock Coverage 29 ratings · 2026-11-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
KURA
Kura Oncology
 Oct 29, 2026 BUY Strong Buy
+155.5% avg upside
27 analysts
$15.00
46.26% Upside
 -31.8% ·
BNTX
BioNTech SE
 Oct 26, 2026 BUY Strong Buy
+48.9% avg upside
28 analysts
$135.00
53.21% Upside
 -1.1% ·
SMMT
Summit Therapeutics
 Oct 26, 2026 BUY Strong Buy
+83.4% avg upside
29 analysts
$33.00
105.85% Upside
 +11.5% ·
CATX
Perspective Therapeutics
 Oct 23, 2026 BUY Strong Buy
+759.3% avg upside
24 analysts
$8.00
595.74% Upside
 -50.9% ·
KR:005930
Samsung Electronics
 Oct 16, 2026 BUY Strong Buy
+40.8% avg upside
9 analysts
$440000.00
95.57% Upside
 +5.1% ·
NBTX
Nanobiotix
 Sep 25, 2026 HOLD Strong Buy
+25.1% avg upside
6 analysts
$30.00
4.35% Downside
 -10.7% ·
ENGN
enGene Holdings
 Sep 16, 2026 HOLD Buy
+553.6% avg upside
13 analysts
$2.00
30.67% Upside
 -8.4% ·
SNDX
Syndax Pharmaceuticals
 Aug 21, 2026 BUY Strong Buy
+155.4% avg upside
27 analysts
$33.00
141.80% Upside
 -51.4% ·
CGON
CG Oncology, Inc.
 Aug 21, 2026 BUY Strong Buy
+33.1% avg upside
17 analysts
$90.00
39.23% Upside
 -18.8% ·
IOVA
Iovance Biotherapeutics
 Aug 20, 2026 HOLD Strong Buy
+83.7% avg upside
26 analysts
$7.00
17.50% Downside
 -3.2% ·
CGEM
Cullinan Management
 Aug 17, 2026 BUY Strong Buy
+135.1% avg upside
16 analysts
$27.00
79.60% Upside
 -45.1% ·
KYMR
Kymera Therapeutics
 Aug 05, 2026 BUY Strong Buy
-9.7% avg upside
39 analysts
$128.00
1.07% Upside
 +24.7% ·
NRIX
Nurix Therapeutics
 Jul 22, 2026 BUY Strong Buy
+22.5% avg upside
28 analysts
$31.00
15.59% Upside
 -35.2% ·
CLDX
Celldex
 Jun 16, 2026 BUY Strong Buy
+42.9% avg upside
28 analysts
$45.00
49.46% Upside
 -12.5% ·
JANX
Janux Therapeutics Inc
 Apr 15, 2026 HOLD Strong Buy
+159.3% avg upside
22 analysts
$15.00
14.12% Downside
 +16.3% ·
AU:TLX
Telix Pharmaceuticals
 Apr 08, 2026 BUY Strong Buy
+103.1% avg upside
14 analysts
$31.00
136.17% Upside
 +25.9% ·
JSPR
Jasper Therapeutics
 Apr 02, 2026 HOLD Strong Buy
+5062.9% avg upside
18 analysts
$1.50
188.31% Upside
 -24.4% ·
MRNA
Moderna
 Jan 07, 2026 HOLD Hold
-48.5% avg upside
38 analysts
$34.00
84.76% Downside
 +638.2% ·
VRTX
Vertex Pharmaceuticals
 Nov 07, 2025 BUY Strong Buy
-20.5% avg upside
62 analysts
$546.00
2.37% Downside
 +32.5% ·
GILD
Gilead Sciences
 Oct 31, 2025 HOLD Strong Buy
-27.3% avg upside
66 analysts
$112.00
34.36% Downside
 +46.0% ·
IDYA
IDEAYA Biosciences
 Oct 24, 2025 BUY Strong Buy
+48.2% avg upside
31 analysts
$50.00
56.49% Upside
 +18.9% ·
JP:6525
Kokusai Electric Corporation
 Apr 02, 2025 HOLD Strong Buy
+8.6% avg upside
9 analysts
$2690.00
61.05% Downside
 +130.8% ·
JP:8035
Tokyo Electron
 Feb 26, 2025 BUY Strong Buy
+209.1% avg upside
12 analysts
$34600.00
263.69% Upside
 +94.8% ·
JP:6758
Sony
 Jan 15, 2025 BUY Strong Buy
+12.8% avg upside
15 analysts
$3900.00
1.37% Downside
 +21.1% ·
AGEN
Agenus
 Sep 29, 2022 BUY Strong Buy
+72.3% avg upside
19 analysts
$5.00
26.89% Downside
 -44.1% ·
MGNX
MacroGenics
 Jul 18, 2022 HOLD Buy
+638.9% avg upside
25 analysts
$5.00
108.26% Upside
 +44.6% ·
NKTX
Nkarta
 May 16, 2022 BUY Strong Buy
+1080.5% avg upside
16 analysts
$40.00
2464.04% Upside
 -67.6% ·
XNCR
Xencor
 May 09, 2022 BUY Strong Buy
+31.8% avg upside
29 analysts
$54.00
81.06% Upside
 +8.8% ·
ACET
Adicet Bio
 Mar 30, 2022 BUY Strong Buy
+665.1% avg upside
14 analysts
$28.00
718.76% Upside
 · ·
🔒 24 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Dai — Frequently Asked Questions
How accurate are David Dai's stock ratings?
Based on the calls 13Foresight could measure, about 50% of David's ratings were profitable over a one-year hold, with an average return of +17.0% per rating, or +11.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Dai is currently ranked #1555 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on KURA, BNTX, SMMT, CATX, KR:005930, NBTX, ENGN, SNDX, CGON, IOVA, CGEM, KYMR and 17 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.